Content

MOTS-c Peptide Benefits: Rodent Depth, Human Hints

Creator: Nadia Okonjo, Health Writer
Published: 2026-08-09

MOTS-c is a peptide your mitochondria encode themselves — and it is studied for how cells handle fuel. The rodent evidence runs deep; the human evidence is just beginning.

Nadia Okonjo, Health Writer August 9, 2026 16 min read

A woman in a cream sweater walking a tree-lined path in morning light

The short version

MOTS-c is a 16-amino-acid peptide (sequence MRWQEMGYIFYPRKLR, about 2.1 kDa) encoded by mitochondrial DNA inside the 12S rRNA gene rather than by the nucleus — one of a small family called mitochondrial-derived peptides.
Its best-mapped action is indirect AMPK activation: MOTS-c disrupts the folate one-carbon cycle, blocking purine synthesis so the intermediate AICAR accumulates (more than 20-fold in overexpressing cells) and activates AMPK at Thr172. No cell-surface receptor for MOTS-c has ever been identified.
The strongest intervention data are rodent: seven days of treatment restored insulin-stimulated glucose uptake in 12-month-old mice to 3-month-old levels, and 22-month-old mice given 15 mg/kg for two weeks doubled their running time.
Human data are mostly observational: a single cycling bout raised skeletal-muscle MOTS-c 11.9-fold in ten healthy young men, circulating levels fall with age, and they are lower in people with type 2 diabetes than in healthy controls.
Human interventional evidence exists but is early — the analog CB4211 completed a Phase 1a/1b trial (n=88) meeting its primary safety endpoint, and MOTS-c itself entered a Phase 2a trial (NCT07505745, n=120 estimated) in February 2026.
MOTS-c is not FDA-approved for any indication and no approved MOTS-c drug product exists in the United States; where it is dispensed at all, it is dispensed as a compounded prescription medication.

MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial genome — specifically within a short open reading frame in the 12S rRNA gene — rather than in the cell nucleus, where nearly every other human peptide originates. Researchers at the University of Southern California described it in 2015. If you are reading about MOTS-c peptide benefits because you are weighing whether to raise it with a provider, the honest summary is that the evidence runs deep in rodents, narrow but real in people, and is currently being tested in one ongoing human trial.

That summary is more useful than it sounds, because most of what circulates about this peptide quietly hides its species. A result described as occurring in "subjects" is usually a result in mice. Below, every number carries the population it came from.

MOTS-c is not FDA-approved for any indication; where it is available through a telehealth service like Promise, it is dispensed as a compounded medication on prescription.

What MOTS-c is, and why a mitochondrial peptide is unusual

MOTS-c — Mitochondrial Open reading frame of the Twelve S rRNA type-c — is a 16-residue peptide, sequence MRWQEMGYIFYPRKLR, transcribed from a short open reading frame inside the mitochondrial 12S rRNA gene (MT-RNR1). Almost every peptide in the human body is written from nuclear DNA. MOTS-c is written from the organelle's own genome, which is why it belongs to a class called mitochondrial-derived peptides, or MDPs.

For decades mitochondrial DNA was assumed to encode nothing but the machinery of oxidative phosphorylation — the parts list for making ATP. The MDPs broke that assumption. Changhan Lee, Pinchas Cohen and colleagues at the USC Leonard Davis School of Gerontology published the founding MOTS-c paper in Cell Metabolism in 2015, and the peptide turned out to be well conserved across species.

The direction of travel is what makes it unusual. Most signalling runs nucleus-to-mitochondrion; MOTS-c runs the other way. Under metabolic stress it translocates into the nucleus and engages stress-adaptation gene programmes — antioxidant-response-element-linked genes and AMPK-responsive transcription factors. That translocation was established in a 2018 Cell Metabolism paper; a 2023 review in the Journal of Translational Medicine puts the timing at as early as 30 minutes after stress induction, resolving within 24 hours, and notes the move is AMPK-dependent, so AMPK sits both upstream and downstream of the same loop.

One thing is worth stating plainly rather than leaving implied: no cell-surface receptor for MOTS-c has been identified. Most peptide medicines are understood through the receptor they occupy. MOTS-c is not, and that is a genuine gap in the science, not a technicality. Tissues where MOTS-c activity has been studied include skeletal muscle (the main one), circulating plasma, liver, pancreatic islet β-cells and the myocardium. It sits in Promise's Energy & Focus category alongside other compounds aimed at mitochondrial and cellular-energy biology.

How MOTS-c works inside the cell

The best-mapped route is indirect, and it runs through a metabolic detour rather than a receptor. MOTS-c interferes with the folate one-carbon cycle; that blocks de novo purine biosynthesis; the purine-pathway intermediate AICAR piles up; AICAR mimics AMP; and AMP mimetics activate AMP-activated protein kinase. In cells stably overexpressing MOTS-c, Lee and colleagues measured AICAR more than 20-fold above controls.

Step by step:

Folate cycle interference. Lee 2015 found depletion of 5-methyl-tetrahydrofolate with elevated homocysteine — the biochemical fingerprint of a stalled one-carbon cycle.
Purine synthesis blocked. De novo purine biosynthesis depends on that cycle, so it slows.
AICAR accumulates. The intermediate 5-aminoimidazole-4-carboxamide ribonucleotide builds up behind the block — more than 20-fold in the overexpressing cell lines.
AMPK is activated. AICAR acts as an AMP mimetic. The readout is phosphorylation of the AMPK α-subunit at Thr172, dose- and time-dependent, with a glycolytic response within 24 hours.
The cell switches modes. Activated AMPK pushes a cell away from anabolic storage and toward catabolic energy production: more glucose uptake, more fatty-acid oxidation.

Downstream of that, metabolomic work reports three pathways reduced under MOTS-c — sphingolipid metabolism, monoacylglycerol metabolism and dicarboxylic acid metabolism. The same three are characteristically elevated in metabolic-dysfunction models, so the direction of change runs opposite to the dysfunction signature. That is a directional observation from cell and animal systems, not a clinical outcome.

One wrinkle cuts against the simple story. In the 2025 rat heart study below, MOTS-c-treated cardiac mitochondria showed increased oxidative-phosphorylation respiration and increased reactive oxygen species — a hormetic profile, not an antioxidant-suppressive one. And in human skeletal muscle, MOTS-c expression was not associated with antioxidant-response-element-related genes, the opposite of what cell-culture models predicted. Anyone selling MOTS-c as a straightforward antioxidant is ahead of the data.

What are the researched MOTS-c peptide benefits?

Almost every intervention result published on MOTS-c is a rodent result. In mice and rats, MOTS-c has improved insulin sensitivity, prevented diet-induced obesity, restored mitochondrial respiration in a diabetic heart model and improved physical performance. In humans, the published data are observational — levels rise acutely with exercise, fall with age, and are lower in type 2 diabetes — plus two interventional trials, one completed on an analog and one ongoing on MOTS-c itself.

Question	Human evidence	Rodent and cell evidence
Insulin sensitivity	Circulating MOTS-c is lower in people with type 2 diabetes than in healthy controls (Kong 2025 human arm). No completed interventional readout.	Glucose infusion rate improved ~30% in high-fat-diet mice after 7 days; insulin-stimulated glucose uptake in 12-month-old mice restored to 3-month-old levels (Lee 2015).
Body weight and liver fat	None published.	0.5 mg/kg/day prevented diet-induced obesity in mice without altering caloric intake, and reduced hepatic lipid accumulation (Lee 2015).
Physical performance	Resting serum MOTS-c correlated with jump power, jump force, overall muscle mass and leg muscle mass in 20 physically active volunteers; no correlation with peak VO₂ (Domin 2023).	22-month-old mice at 15 mg/kg for 2 weeks: running time ×2, distance ×2.16, and 17% reached final sprint speed vs 0% untreated (Reynolds 2021).
Exercise response	Single cycling bout in 10 sedentary healthy young men: muscle MOTS-c ↑11.9-fold, plasma ↑1.6-fold during exercise (Reynolds 2021).	The mouse arm of the same paper administered MOTS-c rather than measuring exercise-induced levels (Reynolds 2021).
Aging	Muscle expression ~1.5-fold higher in middle-aged and older men than young men; circulating levels decline with age (D'Souza 2020).	Mouse work spans ages 3–32 months (Lee 2015).
Cardiac function	None published.	Male Wistar rats in a type 2 diabetes model: 15 mg/kg/day for 3 weeks moved fasting glucose toward control values and reduced left-ventricular wall thickness ~8% (Pham 2025).
Pancreatic islets	Circulating MOTS-c lower in type 2 diabetes (Kong 2025).	Aged C57BL/6 mouse islets showed reduced senescence markers ex vivo; S961-treated and NOD mice showed improved islet senescence and glucose intolerance (Kong 2025).

Read that table as a map of where the evidence is dense and where it is empty. The rodent column is substantial — multiple labs, multiple tissues, doses from 0.5 to 15 mg/kg/day. The human column is five observational datasets, one completed Phase 1a/1b trial of an analog, and one Phase 2a trial of MOTS-c itself still enrolling. Those are different kinds of knowledge, and conflating them is how peptide marketing goes wrong. Catalog detail for what Promise actually dispenses lives on the MOTS-c product page.

Exercise, muscle and MOTS-c

Exercise raises MOTS-c, and this is one of the few places the human data are direct. In the clearest experiment, ten sedentary healthy young men (24.5 ± 3.7 years, BMI 24.1 ± 2.1) completed a single acute bout of ten 60-second cycling intervals at individually determined peak power with 75 seconds of recovery between intervals. Skeletal-muscle MOTS-c rose 11.9-fold after exercise and was still elevated four hours later; plasma MOTS-c rose 1.6-fold during exercise and 1.5-fold immediately after, returning to baseline by the four-hour mark.

The same 2021 Nature Communications paper ran the reverse experiment in mice — giving MOTS-c rather than measuring it. Mice at 2, 12 and 22 months received 5–15 mg/kg intraperitoneally, daily for two weeks, with a late-life cohort dosed three times weekly. The 22-month-old animals at 15 mg/kg doubled their running time and increased running distance 2.16-fold; 17% of treated mice reached the final sprint speed of the protocol against none of the untreated. Grip strength, stride length and rotarod performance also improved. Every one of those numbers is a mouse number.

Two human cross-sectional studies fill in the correlational picture. A preliminary 2023 study of 20 physically active volunteers (17 men, three women, median age 30, none in a structured training programme) measured resting serum MOTS-c against five consecutive countermovement jumps and a cardiopulmonary exercise test to exhaustion. MOTS-c correlated positively with average jump power, average and maximal jump force, overall muscle mass and leg muscle mass — and showed no correlation with peak VO₂ or body-fat percentage.

A 2022 pilot compared 30 non-athlete controls with 75 professional athletes (47 low-to-moderate endurance, 28 high endurance) using ELISA. Professional athletes had lower serum MOTS-c and higher humanin than sedentary controls. One detail gets misreported often enough to be worth stating precisely: MOTS-c did not differ between the moderate-endurance and high-endurance subgroups. The endurance gradient in that study belonged to humanin, a different mitochondrial-derived peptide. The authors framed the athlete-versus-control difference as a speculative adaptation to chronic endurance training, in a paper they themselves called a pilot.

Aging: two compartments moving in opposite directions

Circulating MOTS-c falls with age while skeletal-muscle MOTS-c rises — the same peptide moving in opposite directions in two compartments. In healthy men across three age bands (18–30, 45–55 and 70–81 years), muscle MOTS-c expression was roughly 1.5-fold higher in the two older bands than in the young band, while plasma levels declined with age.

The tempting interpretation is that muscle compensates for a failing systemic supply, but the authors of that 2020 Aging paper did not claim it. They associated the rise with slow-type myofiber markers and read it as a signature of the fast-to-slow fiber-type transition that accompanies aging. In the older group, MOTS-c also tracked with muscle quality, measured as maximal leg-press load relative to thigh cross-sectional area.

On genetics, a variant called m.1382A>C sits inside the mitochondrial reading frame that encodes MOTS-c, and it is largely restricted to Northeast Asian populations. A 2015 paper in Aging Cell proposed that it might contribute to exceptional longevity — and it is worth knowing that this is a three-page hypothesis piece whose own title ends in a question mark. It is an interesting lead, not evidence that MOTS-c extends human lifespan.

The rodent aging data are firmer within their species. In the founding 2015 work, seven days of MOTS-c treatment restored insulin-stimulated glucose uptake in 12-month-old mice to the level of 3-month-old mice, in animals studied across a 3-to-32-month age span.

The 2025 studies: a diabetic rat heart, and mouse and human islets

Two 2025 papers moved the field into specific organs: a rat heart study published 30 June 2025 in Frontiers in Physiology by the Auckland Bioengineering Institute, and a pancreatic islet study published in Experimental & Molecular Medicine in August 2025 by Seoul National University Hospital with the Harvard T.H. Chan School of Public Health and the Broad Institute of MIT and Harvard.

The Auckland study used 30 male Wistar rats, 6–7 weeks old and 150–200 g. Diabetes was induced with a high-fat diet (43% of digestible energy from lipid) for 15 weeks plus low-dose streptozotocin (25 mg/kg) at week 8, and MOTS-c was given at 15 mg/kg/day intraperitoneally during weeks 12–15. Untreated diabetic rats showed fasting glucose around 24 mmol/L against roughly 8 mmol/L in controls, 13% lower mitochondrial oxygen flux at oxidative phosphorylation, and left-ventricular hypertrophy. Treated animals moved fasting glucose back toward control values, showed about an 8% reduction in left-ventricular wall thickness, higher OXPHOS respiration together with higher ROS, increased citrate synthase activity, and decreased ATP hydrolysis under anoxia. The authors positioned MOTS-c as a useful tool for investigating diabetic-related cardiomyopathy and mitochondrial dysfunction — a preclinical framing, in rats.

The Seoul-led study reported that MOTS-c levels decrease with aging and senescence in pancreatic islet cells. Treating aged C57BL/6 mouse islets ex vivo reduced senescence by shifting nuclear gene expression and metabolites tied to cellular aging; in vivo, S961-treated mice and non-obese diabetic mice showed improved islet senescence and glucose intolerance. The human arm was observational: circulating MOTS-c was lower in people with type 2 diabetes than in healthy controls. The authors suggested MOTS-c could act as a senotherapeutic agent — a suggestion, made from mouse islets and human plasma levels.

NAD⁺, SIRT1 and the second mechanistic arm

AMPK is not the only arm. SIRT1 — a deacetylase that cannot function without NAD⁺ — is partially required for some MOTS-c effects: pharmacological or genetic inhibition of SIRT1 significantly reduced the glucose-stimulated glycolysis rate that MOTS-c otherwise produced. SIRT1 in turn helps mediate AMPK activation via NAD⁺ and deacetylates PGC-1α, the coactivator that drives mitochondrial biogenesis.

MOTS-c has also been reported to raise NAD⁺ itself. That specific claim is more weakly sourced than the folate–AICAR–AMPK axis, and it should be held loosely rather than repeated as established. What is better supported is the dependency running the other way: SIRT1 needs NAD⁺ to work at all, and NAD⁺ availability is itself a variable that changes with age. That makes the NAD⁺ pool part of the context MOTS-c acts in, not a mechanism MOTS-c owns.

Which is why NAD+ sits in the same Energy & Focus category rather than inside this article's mechanism section. It is a different molecule addressing overlapping biology — not a substitute for MOTS-c, not evidence for MOTS-c, and not something to stack on assumption. Whether either is appropriate is a clinical judgement made in a visit, not a reading exercise.

How MOTS-c compares with other peptides

MOTS-c differs from most peptide medicines in where it acts. Growth-hormone secretagogues work upstream, at the pituitary, prompting release of a hormone that then travels to tissues. MOTS-c skips the endocrine step: it acts inside the cell, moving into the nucleus and engaging gene programmes directly. Within its own family, the division of labour is by research focus rather than by structure.

Peptide or class	Origin	Main research focus	How it acts
MOTS-c	Mitochondrial DNA, 12S rRNA reading frame	Energy metabolism, insulin sensitivity	Translocates to the nucleus under stress; AMPK-dependent; no known cell-surface receptor
Humanin	Mitochondrial DNA	Neuroprotection and cell survival	Cytoprotective signalling; higher in trained athletes than controls in one pilot
SHLP1–6 (small humanin-like peptides)	Mitochondrial DNA	A group of six peptides in the same MDP family	Under investigation
Growth-hormone secretagogues (e.g. sermorelin, CJC-1295/ipamorelin, tesamorelin)	Synthetic GHRH analogs or ghrelin-receptor agonists	Growth-hormone axis	Stimulate pituitary hormone release — an endocrine step upstream of the cell

Promise's catalog also includes SS-31, another mitochondrially directed peptide in the same Energy & Focus category, with a different mechanism and a separate evidence base. Sharing an organelle is not the same as sharing a mechanism; none of these are interchangeable.

What is still unknown — and it is a lot

Three gaps matter more than the rest, and none is closed. No receptor has been identified. No peer-reviewed human pharmacokinetic half-life has been published — reviews describe mitochondrial-derived peptides qualitatively as low in bioavailability, poor in stability and short in half-life, and as tending to persist at injection sites, but no human number exists in the literature. Figures circulating online do not trace to peer-reviewed pharmacokinetic work. And route matters: rodent studies used intraperitoneal injection, which is not a human route; both human trials used subcutaneous injection. The field's answer to those delivery limits has been to engineer modified analogs for better stability, and CB4211 is the worked example.

A fourth point is about how to read the literature rather than what is in it. Several foundational MOTS-c papers — the 2015 discovery paper, the 2021 exercise paper and the 2020 aging-muscle paper — share authors who have been consultants and shareholders of CohBar, Inc., the company that developed the MOTS-c analog CB4211. These relationships are disclosed in the literature. It does not invalidate the findings, and it is normal in translational science, but a small founding-author group with a commercial stake is context worth having when a field's evidence base is this concentrated.

Human trials: what has actually been tested in people

Two interventional programmes exist. CB4211, a MOTS-c analog developed by CohBar, completed a Phase 1a/1b trial (NCT03998514) with 88 participants. MOTS-c itself entered a Phase 2a trial (NCT07505745) in February 2026, sponsored by Hudson Biotech, with 120 participants estimated. Neither supports a claim about outcomes; together they mean the compound is under formal clinical study rather than absent from it.

The CB4211 Phase 1a portion assessed safety and tolerability after seven days of dosing. Phase 1b was randomised, double-blind and placebo-controlled: 25 mg once daily by subcutaneous injection for four weeks in 20 adults with obesity and non-alcoholic fatty liver disease. Topline results in August 2021 reported that the primary safety endpoint was met with no serious adverse events, and that exploratory endpoints showed significant reductions in ALT and AST, a significant decrease in glucose, and a trend toward lower body weight. Exploratory endpoints in a 20-person arm are hypothesis-generating by design — they are the reason to run a Phase 2, not a substitute for one.

The MOTS-c trial is that Phase 2: randomised 1:1, double-blind, placebo-controlled, enrolling adults with prediabetes and overweight or obesity. Participants receive a fixed once-daily subcutaneous dose for 12 weeks alongside standardised lifestyle counselling, with safety follow-up through week 16 and insulin sensitivity versus placebo as the primary aim. It began on 2 February 2026 and was recruiting as of August 2026. Results are not yet available, and nobody — including anyone selling the compound — knows what they will show.

Before you start an intake

MOTS-c is not FDA-approved for any indication, and no approved MOTS-c drug product exists in the United States. Through Promise it is dispensed as a compounded medication, prepared by a licensed pharmacy. Every request is reviewed by a licensed provider in our clinician network who prescribes or declines based on your medical history and the clinical picture — not everyone qualifies, and a provider may decline. That review is where dosing, monitoring and whether MOTS-c is appropriate at all get decided; nothing in this article is a regimen to follow.

This article is health information, not medical advice. It does not diagnose any condition, it is not a substitute for a conversation with a licensed clinician who knows your history, and it is not a recommendation to start any medication.

References

Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism 2015;21(3):443–454. https://pmc.ncbi.nlm.nih.gov/articles/PMC4350682/
Wan W, Zhang L, Lin Y, Rao X, Wang X, Hua F, Ying J. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. Journal of Translational Medicine 2023;21:36. https://pmc.ncbi.nlm.nih.gov/articles/PMC9854231/
Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications 2021;12:470. https://pmc.ncbi.nlm.nih.gov/articles/PMC7817689/
D'Souza RF, Woodhead JST, Hedges CP, Zeng N, Wan J, Kumagai H, Lee C, Cohen P, Cameron-Smith D, Mitchell CJ, Merry TL. Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition. Aging (Albany NY) 2020;12(6):5244–5258. https://pmc.ncbi.nlm.nih.gov/articles/PMC7138593/
Domin R, Pytka M, Żołyński M, Niziński J, Rucinski M, Guzik P, Zieliński J, Ruchała M. MOTS-c serum concentration positively correlates with lower-body muscle strength and is not related to maximal oxygen uptake — a preliminary study. International Journal of Molecular Sciences 2023;24(19):14951. https://pmc.ncbi.nlm.nih.gov/articles/PMC10573682/
Alser M, Ramanjaneya M, Rizwana Anwardeen N, Donati F, Botrè F, Jerobin J, Bettahi I, Mohamed NA, Abou-Samra AB, Elrayess MA. The effect of chronic endurance exercise on serum levels of MOTS-c and humanin in professional athletes. Reviews in Cardiovascular Medicine 2022;23(5):181. https://pmc.ncbi.nlm.nih.gov/articles/PMC11273660/
Fuku N, Pareja-Galeano H, Zempo H, Alis R, Arai Y, Lucia A, Hirose N. The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity? Aging Cell 2015;14(6):921–923. https://pmc.ncbi.nlm.nih.gov/articles/PMC4693465/
Pham T, Taberner A, Hickey A, Han JC. Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart. Frontiers in Physiology 2025;16:1602271. https://pmc.ncbi.nlm.nih.gov/articles/PMC12257629/
Kong BS, Lee H, L'Yi S, Hong S, Cho YM. Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes. Experimental & Molecular Medicine 2025;57(8):1861–1877. https://pmc.ncbi.nlm.nih.gov/articles/PMC12411631/
CohBar, Inc. A study of CB4211 in subjects with obesity and non-alcoholic fatty liver disease (NAFLD). ClinicalTrials.gov identifier NCT03998514, Phase 1a/1b, completed, n=88. https://clinicaltrials.gov/study/NCT03998514
Hudson Biotech. A Phase 2a study of MOTS-c in adults with prediabetes and overweight or obesity. ClinicalTrials.gov identifier NCT07505745, Phase 2a, recruiting, n=120 estimated. https://clinicaltrials.gov/study/NCT07505745
Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism 2018;28(3):516–524.e7. https://pubmed.ncbi.nlm.nih.gov/29983246/

Common questions

What is MOTS-c?

MOTS-c is a 16-amino-acid peptide with the sequence MRWQEMGYIFYPRKLR, encoded by a short open reading frame inside the mitochondrial 12S rRNA gene rather than by nuclear DNA. It belongs to a small family called mitochondrial-derived peptides, alongside humanin and the small humanin-like peptides SHLP1 through SHLP6. Researchers at the University of Southern California described it in 2015.

What are the researched MOTS-c peptide benefits for metabolic health?

Almost all of them are rodent findings. In high-fat-diet mice, seven days of MOTS-c improved glucose infusion rate by about 30%, and 0.5 mg/kg/day prevented diet-induced obesity without changing food intake. In rats with type 2 diabetes, it restored mitochondrial respiration in the heart. The human data are observational — circulating levels are lower in type 2 diabetes — plus one completed Phase 1a/1b trial of an analog and one ongoing Phase 2a trial.

What does MOTS-c actually do inside a cell?

Its best-characterised route is indirect. MOTS-c disrupts the folate one-carbon cycle, which blocks de novo purine biosynthesis and causes the intermediate AICAR to accumulate — more than 20-fold in cells engineered to overexpress the peptide. AICAR mimics AMP, which activates AMPK through phosphorylation at Thr172, shifting the cell toward using energy rather than storing it.

Are there any human studies of MOTS-c?

Yes, in two forms. Observational studies have measured natural MOTS-c levels in people after exercise, across age bands, in professional athletes, and in type 2 diabetes. Interventional evidence is earlier: the analog CB4211 completed a Phase 1a/1b trial with 88 participants (NCT03998514), and MOTS-c itself entered a Phase 2a trial of 120 estimated participants in February 2026 (NCT07505745), which is recruiting.

Does exercise change MOTS-c levels?

Yes, acutely and substantially. In ten sedentary healthy young men performing a single bout of ten 60-second cycling intervals, skeletal-muscle MOTS-c rose 11.9-fold and remained elevated four hours later, while plasma MOTS-c rose 1.6-fold during exercise and returned to baseline within four hours. The mouse arm of that same study went the other direction, administering MOTS-c rather than measuring what exercise did to endogenous levels.

Do MOTS-c levels change as you get older?

They move in opposite directions depending on where you measure. In healthy men across three age bands — 18–30, 45–55 and 70–81 years — skeletal-muscle MOTS-c expression was roughly 1.5-fold higher in the two older bands, while circulating levels declined with age. The authors linked the muscle increase to a fast-to-slow shift in myofiber composition rather than to a proven compensation mechanism.

Do trained athletes have higher MOTS-c than untrained people?

Lower, in the one study that compared them directly. Among 75 professional athletes and 30 non-athlete controls measured by ELISA, athletes had lower serum MOTS-c and higher humanin than sedentary controls, and MOTS-c did not differ between the moderate-endurance and high-endurance subgroups. The authors described the work as a pilot and the interpretation as speculative.

Is MOTS-c FDA-approved?

No. MOTS-c is not FDA-approved for any indication, and no approved MOTS-c drug product exists in the United States. It is dispensed as a compounded medication, prepared by a licensed pharmacy after a licensed provider prescribes it. The only MOTS-c product under formal FDA drug review is the investigational one being studied in the ongoing Phase 2a trial.

How is MOTS-c different from peptides like sermorelin or tesamorelin?

They act at completely different levels. Growth-hormone-releasing peptides stimulate the pituitary gland to release growth hormone, an endocrine step upstream of the tissues that respond. MOTS-c does not engage that axis at all. It works inside the cell, translocating into the nucleus under metabolic stress and engaging AMPK-linked stress-response gene programmes directly.

Does MOTS-c bind to a receptor?

No cell-surface receptor for MOTS-c has been identified. This is one of the real gaps in the field, because most peptide medicines are understood through the receptor they occupy. Current models describe an intracellular mechanism: under metabolic stress MOTS-c moves into the nucleus, detectable as early as 30 minutes after stress induction and resolving within 24 hours, and that translocation requires AMPK.

How long does MOTS-c stay in the body?

No peer-reviewed human pharmacokinetic half-life for MOTS-c has been published. Reviews describe mitochondrial-derived peptides qualitatively as having low bioavailability, poor stability and short half-lives, and as tending to persist at injection sites. Numbers circulating online do not trace back to peer-reviewed pharmacokinetic studies, so the honest answer is that the human figure is unpublished.

How do researchers measure MOTS-c?

In blood and tissue, primarily with immunoassays — ELISA in the athlete study, an immunoassay in the aging-muscle study. Research groups add metabolomics and proteomics to trace downstream pathway changes, genotyping to examine variants such as m.1382A>C within the MOTS-c reading frame, and mass spectrometry as independent confirmation that the peptide is present.

What should I ask a provider about MOTS-c?

Bring what you are trying to change, your medical history, your current medications and any recent lab work. A licensed provider decides whether MOTS-c is appropriate, what regimen and monitoring would apply, and whether something else fits your situation better. Because MOTS-c is compounded and still investigational, the conversation should cover what is known, what is unpublished, and what would count as a reason to stop.